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OBJECTIVES This study sought to determine the effect of aggressive 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy on surrogate markers in
non-ischemic cardiomyopathy (NICM) patients and average low-density lipoprotein (LDL)
concentrations.
BACKGROUND The effects of statins may well go beyond lipid lowering, and these pleiotropic effects may be
of benefit in the treatment of heart failure.
METHODS Fifteen patients with NICM on standard maximized heart failure medication were enrolled
in a randomized, double-blinded, placebo-controlled, crossover trial. Patients received 80 mg
atorvastatin (ATV) or matching placebo for a 12-week treatment period with a minimum of
an 8-week washout period. The following surrogate markers were evaluated: N-terminal-pro
brain natriuretic peptide, high-sensitivity C-reactive protein, oxidized LDL antibody, soluble
receptor tumor necrosis factor, tumor necrosis factor-alpha, circulating levels of vascular
adhesion molecule-1, intercellular adhesion molecule-1, P-selectin, non-invasive endothelial
function studies, and heart rate variability.
RESULTS After ATV therapy, there was a significant decrease in LDL concentration from 110  27
mg/dl to 55  18 mg/dl (p  0.05). There were no differences between ATV and placebo
with regard to the surrogate markers measured.
CONCLUSIONS Based on these findings, it seems that the administration of high-dose statins to a heart failure
population with modest LDL levels and no other indication for statin therapy was neither
beneficial nor detrimental as determined by surrogate marker measures. Further studies are
needed to determine whether there is an appropriate patient population and optimal dose
(LDL concentration) for the treatment of systolic heart failure with statin therapy. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.087Coll Cardiol 2006;47:338–41) © 2006 by the American College of Cardiology Foundation
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aecent evidence has suggested that inhibition of 3-hydroxy-
-methylglutaryl-coenzyme A (HMG-CoA) reductase may
e of benefit in patients with ischemic and non-
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schemic cardiomyopathy (1–7). However, there are limited
ata to suggest that low cholesterol levels in the setting of
eart failure may be detrimental (8,9).
It is reasonable to derive that the use of HMG-CoA
eductase inhibitors (statins) may be of benefit for the
reatment of heart failure. The potential benefits of statin
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ccepted June 27, 2005.herapy are the findings that in both human and animal
odels HMG-CoA reductase inhibition can improve nitric
xide availability, endothelial function, and heart rate vari-
bility, along with reducing markers of inflammation and
ytokine activation. Conversely, it has been postulated that
oo great a reduction in cholesterol or coenzyme Q10 may
orsen heart failure (8–10).
To further our understanding of the role of statins, we
tudied the effect of aggressive HMG-CoA reductase inhi-
ition in non-diabetic patients with non-ischemic cardio-
yopathy (NICM) and average low-density lipoprotein
LDL) concentrations. This cohort of patients was selected
o determine whether statins would be of benefit in patients
ho would otherwise not be considered for statin therapy.
ETHODS
total of 15 non-diabetic patients with NICM completed
randomized, double-blinded, placebo-controlled, cross-
ver trial evaluating the effect of atorvastatin 80 mg once per
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January 17, 2006:338–41 High-Dose Statin Therapy for Heart Failureay (ATV) on surrogate markers of heart failure. Random-
zation was achieved using a block design (n  10) and a
andom numbers table for a total of 20 patients. Seven
atients received ATV as initial therapy. After approval
rom the hospital’s Institutional Review Board and before
tudy entry, informed consent was obtained. Inclusion
riteria included a history of congestive heart failure 3
onths secondary to NICM; ejection fraction40% within
2 months; patients receiving maximized individual heart
ailure therapy; or LDL 160 mg/dl. Exclusion criteria
ncluded a New York Heart Association functional class IV
unction; diabetes; or cholesterol-lowering, antioxidant, es-
rogen replacement, or non-steroidal anti-inflammatory
herapy.
Treatment periods for ATV and placebo were 12 weeks.
he washout period between treatments was a minimum of
ight weeks. Patient compliance was determined by tablet
ount. Both ATV and matching placebo were provided by
fizer Inc. (Ann Arbor, Michigan).
ndothelial function. The method has been previously
ublished (11).
eart rate variability. Patients were evaluated for 24 h by
Holter monitor. The data were processed using the
tandard Delmar-Reynolds program incorporating a fast
ourier transform. The time domain analysis of heart rate
ariability included standard deviation of all normal-to-
ormal intervals (ms), standard deviation of the averages of
ormal-to-normal intervals in all 5-min segments (ms), and
he square root of the sum of the squares of differences
etween adjacent normal-to normal-intervals.
iological markers. Plasma samples were obtained from
atients at the start and end of each phase for analysis of
iological markers for heart failure (N-terminal-pro brain
atriuretic peptide [BNP]), inflammation (high-sensitivity
-reactive protein [hsCRP], oxidized LDL-antibody [ox-
DL], soluble receptor tumor necrosis factor [sTNF-R],
umor necrosis factor-alpha [TNF-]), and endothelial
ctivation (circulating levels of soluble vascular adhesion
olecule [sVCAM]-1, soluble intercellular adhesion mole-
ule [sICAM]-1, soluble P-selectin). Analysis of samples
as performed using an enzyme-linked immunosorbent
ssay.
tatistics. Comparisons were made using general linear
Abbreviations and Acronyms
ATV  atorvastatin
HMG-CoA  3-hydroxy-3-methylglutaryl-coenzyme A
hsCRP  high-sensitivity C-reactive protein
LDL  low-density lipoprotein
NICM  non-ischemic cardiomyopathy
oxLDL  oxidized low-density lipoprotein antibody
sICAM  soluble intracellular adhesion molecule
sTNF-R1  soluble receptor tumor necrosis factor
sVCAM  soluble vascular adhesion moleculeodel repeated-measures analysis of variance (SPSS for

Yindows, version 11.5, SPSS Inc., Chicago, Illinois). The
ata are expressed as mean  standard deviation. A value of
 0.05 was considered statistically significant. The study
as estimated to have a power to determine a 25% difference
n 10 to 14 patients for the primary end points: TNF-,
ICAM, sVCAM, and endothelial function.
ESULTS
total of 18 patients were entered in the study, and 15
ompleted all phases. One patient died of sudden cardiac
eath at the end of the 12-week placebo phase, and two
ithdrew unrelated to study drug. Baseline parameters are
hown in Table 1.
Results for surrogate markers are shown in Table 2. No
ignificant differences were seen for any parameter except
or LDL. No differences were observed between the two
aseline measurements for any parameter (either analysis of
ariance or paired t test). When the data were log trans-
ormed or when post-therapy (ATV/placebo) values were
valuated by a paired t test, no significant differences were
ound for any variable (except LDL). Patients had non-
etectable levels at some time points for hsCRP (n 2) and
-selectin (n  4). Statistical analysis was similar when
hese patients were excluded or the assay’s lowest sensitivity
alue was entered as the non-detectable value. The ATV
roup had improvement in the markers for heart rate
ariability, but this was not statistically significant. Unfor-
unately, because of technical difficulties, only 10 patients
ad a complete set of tapes.
There was greater reduction in hsCRP and oxLDL, as
ould be expected for the ATV group. A total of 9 of 15
atients had a decrease in hsCRP in the ATV group, and 5
f 15 for the placebo group. A total of 9 of 15 patients also
ad a decrease in oxLDL, as compared with 6 of 15 for the
lacebo group.
able 1. Patient Demographics
ge (yrs) 56  11
ale/female 9/6
eart rate (beats/min) 74  8
YHA functional class I/II/III 1/12/2
-min walk test (feet) 1,627  212
VEF (%) 25  9
BP (mm Hg) 130  23
BP (mm Hg) 70  8
reatinine (mg/dl) 1.1  0.2
odium (mEq/l) 141  3.8
emoglobin (g/dl) 13.8  1.1
CE inhibitors/ARB (n) 13/15
ydralazine/nitrates (n) 1/15
eta-blockers (n) 12/15
ldosterone antagonists (n) 9/15
igoxin 10/15
oop diuretic 13/15
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; DBP
diastolic blood pressure; LVEF  left ventricular ejection fraction; NYHA  New
ork Heart Association; SBP  systolic blood pressure.
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tudies evaluating statin therapy in left ventricular dysfunc-
ion have shown benefit (1–7). The current study, which
nvestigated the use of high-dose statin therapy in a patient
opulation with modest LDL levels and no other indication
or statin therapy, showed neutral effects on surrogate
arkers of heart failure. A significant decrease in LDL was
ound, and there was an appropriate trend in hsCRP
eduction. However, no clear benefit was seen after the
dministration of 80 mg ATV in this cohort of patients.
onversely, no detrimental effects were observed after ag-
ressive lipid-lowering therapy and resultant low LDL
oncentrations.
Our findings were unexpected based on previous studies
6,7,12). One explanation may be the patient population
hat ended up completing the study. Our patient population
as young with a relatively high blood pressure for heart
ailure patients and a mean LDL of 114 mg/dl. In addition,
of 15 patients had a BNP 200 fmol/ml and 8 of 15
atients had an hsCRP 2.6 mg/ml. In addition, the
aseline values for a number of our surrogate markers seem
o be lower compared with other studies in the literature
13,14). In fact, these markers for the most part were in the
ange that according to the assay’s manufacturer were
onsidered normal. These findings, taken together, suggest
relatively healthy patient group. In relatively healthy
atients already on therapies known to reduce morbidity
nd mortality, it is unlikely for additional therapy to show
arge changes in surrogate markers, especially for markers
hat are already in a normal range.
As previously mentioned, studies specifically in patients
ith hypercholesterolemia or heart failure have shown
enefit in the type of surrogate markers we measured
Table 2. LDL and Markers for Heart Failure,
Endothelial Function, and Vagal Tone
Parameters (Baseline Ranges) ATV-B
LDL (55–161 mg/dl) 110  27
BNP (50–625 fmol/ml) 242  191
hsCRP (ND–11.7 ng/ml) 4.5  3.7
oxLDL (18–117 u/l) 64  29
sTNF-R1 (587–2,377 pg/ml) 1,286  511
TNF- (0.91–3.23 pg/ml) 1.66  0.6
P-selectin (ND–110 ng/ml) 30  19
sICAM (208–414 ng/ml) 276  37
sVCAM (238–1,017 ng/ml) 506  120
FMD (%) 4.9  4.4
NMD (%) 14.8  6.1
SDNN (ms) 116  37
SDANN5 (ms) 102  27
RMSSD (ms) 52  47
*p  0.05 vs. all groups. The range for analysis of variance
ATV  atorvastatin treatment; ATV-B  atorvastatin ba
flow mediated dilation; hsCRP  high-sensitivity C-reactiv
NMD  nitroglycerine mediated dilation; oxLDL  oxidiz
RMSSD  square root of the sum of the squares of differe
standard deviation of the averages of normal-to-normal int
normal-to-normal intervals; sICAM  soluble intracellular
factor; sVCAM  soluble vascular adhesion molecule; TNF6,7,12). Obviously, in patients with hypercholesterolemia shere is generally an elevated inflammatory state that allows
or greater drug effect. In regard to studies in heart failure
atients, there are two prospective studies that show a
enefit in NICM patients (6,7). The first study compared
0 mg/day of simvastatin (n  24) with placebo (n  27)
or 14 weeks (6). The results showed improvement in
jection fraction, BNP, and TNF-. Important differences
etween this study and the current study include higher
DL (154  18 mg/dl, standard error of the mean),
NF-, and lower blood pressure. Given these differences,
his group of patients is perhaps less healthy, has a higher
nflammatory state, and is more likely to respond to statin
herapy as compared with our patients. The other study
valuated eight NICM patients receiving 0.4 mg cerivasta-
in compared with seven patients receiving placebo for 20
eeks (7). The mean LDL was 136.9  15.67 mg/dl
standard error of the mean). Significant effects were ob-
erved in the statin group regarding reduction in hsCRP and
NF-, but no difference in sICAM or LDL. Similar to
he other study, patients in this study had higher LDL
evels.
A concern regarding the use of cholesterol-lowering
gents is that significantly decreasing LDL may be detri-
ental in the setting of heart failure. Reducing the number
f lipoproteins too low may prevent significant binding and
etoxification of endotoxins, resulting in further activation
f proinflammatory mediators and progression of heart
ailure (10). Another concern specific to statin therapy is the
ypothesis that statins may reduce coenzyme Q10 concen-
rations, which may decrease adenosine triphosphate and
ead to the progression of heart failure. This is debatable,
nd the majority of the evidence at this time does not
upport this concept (1–7,15–17). The results from our
mmation, Endothelial Activation,
ATV PBO-B PBO
55  18* 112  29 115  38
228  197 246  182 247  206
3.9  3.1 5.1  4.0 5.8  3.2
55  30 60  28 61  28
1,361  447 1,216  368 1,271  388
1.73  0.5 1.97  0.8 1.82  0.4
23  20 34  33 31  22
277  46 280  48 276  63
514  144 494  172 519  183
3.3  3.8 4.2  2.9 2.4  2.9
13.2  6.2 12.8  5.2 16.6  9.7
133  66 131  40 112  25
117  50 117  32 98  19
59  70 53  52 50  33
s, excluding LDL, was 0.181 to 0.994.
; BNP  N-terminal pro brain natriuretic peptide; FMD 
in; LDL  low-density lipoprotein; ND  not detectable;
L antibody; PBO  placebo; PBO-B  placebo baseline;
etween adjacent normal-to-normal intervals; SDANN5 
in all 5-min segments; SDNN  standard deviation of all
ion molecule; sTNF-R1  soluble receptor tumor necrosis
tumor necrosis factor alpha.Infla
p value
seline
e prote
ed LD
nces b
ervalstudy do not support either of these hypotheses. This is the
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January 17, 2006:338–41 High-Dose Statin Therapy for Heart Failurerst trial that has evaluated high-dose statin therapy in
ICM. Despite having extremely low LDL concentrations,
here were no negative outcomes observed.
In contrast to the above argument, it could be rationalized
hat our neutral effect is in a sense a negative effect.
ignificant reductions in LDL and coenzyme Q10 levels
revented the study from showing positive results. To
irectly answer these questions, a dose-response trail is
equired. However, it is reassuring that if aggressive lipid
owering is required, further activation of inflammatory state
r heart failure progression (as measured by BNP) does not
ccur.
There are a number of limitations in this study, including
small sample size. However, given the findings of our
tudy (small differences and large standard deviations), a
easonable increase in the sample size is unlikely to change
he conclusions, with the exception perhaps of heart rate
ariability and hsCRP. For example, to show a difference
 0.05,  0.2) in BNP or sICAM based on our results,
ore than 1,000 patients would need to be studied. In
ontrast, for hsCRP, the number would be 100 patients.
nother limitation is that this was not a dose-response trial,
nd not all of statins’ pleiotropic effects were measured (e.g.,
nterleukin-6). Finally, there is the inherent limitation of
sing surrogate markers in a short-term trial in place of
ong-term morbidity and mortality end points.
Overall, HMG-CoA reductase inhibition does not seem
o have a major effect on the markers of heart failure,
nflammation, or endothelial activation, and does not im-
rove endothelial function or vagal tone in this cohort of
ICM patients. Based on these findings, it seems that the
dministration of high-dose statins for the treatment of
eart failure in this relatively healthy heart failure popula-
ion may be of limited short-term benefit as determined by
he surrogate markers measured. Higher-risk patients, such
s patients with ischemic cardiomyopathy or with diabetes
nd either ischemic or NICM, may show greater benefit
ith statin therapy. Importantly, no apparent negative
onsequences were observed after aggressive HMG-CoA
eductase inhibition and resultant low LDL concentrations.
owever, the lack of an apparent benefit may also relate to
he resultant low LDL concentrations. Further studies are
eeded to determine whether there is an appropriate patient
opulation and optimal dose (LDL concentration) for theeprint requests and correspondence: Dr. Barry E. Bleske,
niversity of Michigan, College of Pharmacy, 428 Church Street,
nn Arbor, Michigan 48109-1065. E-mail: bbleske@umich.edu.
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